Full Transcript Introduction to Cancer Evolution 0:00 Well, it's my absolute honor to have a Professor Swanton with me here today. 0:04 You are a man that has been studying cancer for a long time. 0:09 You are a clinician scientist, deputy clinical director 0:14 at the Francis Crick Institute, UK, Cancer Research UK. 0:18 You're a chief clinician and your research really can advance 0:23 our knowledge of that cell to cell genetic variability 0:26 within tumors and molecular pathways that drive cancer to. 0:30 So I'm really, really excited about this discussion. 0:33 So thank you so much for for joining me today, Professor Swanton. 0:37 Great pleasure. Hi. Lovely to meet you. 0:40 So can you tell me 0:42 a little bit in regards to that cancer evolution? 0:46 What what it means kind of in everyday language for people to understand. 0:51 Well, I think the 0:53 best way of thinking about cancer evolution is a 0:56 in terms of a disease that never stays the same. 0:59 I think you see this clinically in patients who you treat 1:02 with targeted therapies. 1:04 And over time, tumors acquire resistance 1:08 to therapies or intrinsically resistant to therapies. 1:11 And I think what that tells you is that much like bacteria evolve routes 1:16 towards genetic resistance, soda cancers do the same. 1:20 And we started looking at this about 16, 17 years ago 1:24 when we applied new clonal signaling technologies 1:28 to large renal cancers and found that multiple, 1:32 distinct biopsies in the same tumor would harbor different genetic events. 1:36 Some would be shared across all biopsies, the so-called trunk mutations, 1:40 the early founder events. 1:41 But then as tumors evolve, they acquire mutations 1:44 in some parts of the tumor and some sub clones, but not others. 1:47 And it's that diversity that natural selection acts upon, 1:51 and that diversity can play out in a number of ways genetically 1:54 epigenetic and can occur even through treatment. 1:58 Treatment itself can lead to DNA mutagenesis, but of course 2:01 other other other mutagens like UV light, 2:05 tobacco smoke can also lead to genetic diversity
Tumor Heterogeneity and Trunk Mutations 2:08 that ultimately creates this variability in sub clones in the same tumor 2:12 that allow one or more to become resistant to a drug 2:16 that perhaps the tumor and the patient has never been treated with before. 2:19 And for that sub clone 2:20 to emerge and and results in treatment failure and drug resistance. 2:24 And that's a challenge I think that a lot of kind of 2:27 the normal Joes out there don't really understand. 2:30 We look upon, you know, a tumor as a homogenous type of, of substance 2:36 where, you know, you put a needle and do biopsy in one location 2:39 and then you think that that is kind of the, 2:42 you know, the identity of the all the components within that tumor. 2:47 So how, how, how can you explain for people to really understand 2:54 the complexity that that exists within the tumor and also the challenge 2:58 sometimes with doing biopsies and gaining the appropriate information from that? 3:04 Yeah. 3:05 So I think the first thing to say, yes, it is complicated, but the complexity 3:08 can be distilled into simplicity. 3:12 What is that simplicity? 3:13 It's identifying the founder events in the tumor 3:15 that are shared across every tumor region, in every sub clone. 3:18 These are the trunk mutations. 3:20 And and we know from, 3:22 you know, the last sort of 1015 years of the optimal cellular target. 3:26 So the trunk ones, the ones that are present in every tumor cell. 3:30 So take EGFR or Keras as an example. 3:33 Keras mutant pancreas cancer EGFR moon lung cancer. 3:36 Keras mutant G12, c mutant lung cancer. 3:40 These diseases are optimally treated with Keras and EGFR inhibitors. 3:45 If those those mutations are present in the trunk of the tree, 3:49 which they almost always are when they're present. 3:51 In other words, if R mutations 3:54 in lung cancer are very rarely sub clonal, they're almost always clonal, 3:59 tranquil and tumor origins their founder genetic events that are present 4:03 in every tumor cell and as a result they make very good targets, 4:07 very good drug targets. 4:08 And they'll be found in every biopsy for the most part, with some exceptions. 4:12 So the same pancreatic cancer and many other examples. 4:16 So when you talked a little bit earlier, you talked about treatment failure 4:20 because of the sub clonal diversities and such clonal them meaning 4:24 that you have other drivers sort of say within that tumor. 4:29 And then you, you go with a chemo that attacks a certain component 4:33 of that population, then the tumor, but then you have the diversities 4:38 and making it hard. 4:39 Then for that chemo to impact that, so does does that then evolve that, 4:45 that tumor in, in how it needs to be treated. 4:48 Do we need to reassess and do another 4:51 understanding of its kind of genetic diversity? 4:55 Yeah. 4:55 So there's good examples of this in the literature now. 4:58 So for example, patients who are treated with EGFR inhibitors in the context
Drug Resistance and Clonal Selection 5:02 of non-small cell lung cancer can develop mutations, get so-called gatekeeper 5:07 mutations in in in a, a code on 793 and into methionine mutation. 5:13 And that causes resistance to the first second generation EGFR kinase inhibitors. 5:19 And that that led to the ultimate approval of 5:23 that helps 5:24 combat those mutations and prolonged progression free survival times. 5:28 But of course, evolution is a fickle beast. 5:30 And, you know, there are resistance events to this third generation of EGFR 5:34 tyrosine kinase inhibitors, including things like Mets amplification 5:38 or additional mutations in EGFR, such as C7 nine seven s, 5:43 for which people are developing new drugs for and obviously met inhibitors 5:47 that are required at resistance in sub clones to Austin 5:51 Knibb are also being developed, and there have been some very promising data 5:55 at last week in this regard after Austin Merton had failure. 5:59 So yes, it's very well established that subclinical evolution 6:03 drives drug resistance in those acquired sub clones. 6:06 If analyzed correctly, if they have actionable alterations, 6:09 can sometimes result in further benefits if the appropriate drug is used. 6:15 And so I mean how I usually explain that. 6:18 Then please correct me if this is an inappropriate way to explain it. 6:22 I kind of tell patients that it is almost like you look at a big city, let's say. 6:28 New York and within New York. 6:29 Yes, there are certain components that are there similarities. 6:34 You know, there are all human beings. 6:35 And but then you have Little Italy, you have Chinatown, you have. 6:40 And so you have then these different aspects 6:43 that are very unique for these neighborhoods. 6:45 And they need to be addressed differently. 6:48 Yeah. That's true. 6:49 I think that's not a bad analogy, actually. 6:51 I take it one step further than that, actually. 6:54 And it's an area that we're increasingly interested in is, is crosstalk. 6:58 It's communities. 6:59 It's communities of cells that collaborate to boost the tumor 7:04 genetic potential or the metastatic potential of cells. 7:07 And we are we, for example, have some evidence last year 7:11 showing a disease of aging, clonal hematopoiesis of indeterminate potential. 7:16 This phenomenon where in your bone marrow or bone marrow, stem cells that release 7:20 myeloid white blood cells, that 7:22 that allow us to fight infection and what have you, as we age, 7:25 these stem cells in our bone marrow acquire mutations that make them fitter. 7:29 And those fit, those fitter clones get into the blood 7:32 and they become hyper inflammatory as a result of those mutations 7:36 that I mentioned, two and three, for example. 7:40 And it turns out these these myeloid codes with those so-called chip mutations, 7:44 clonal hematopoiesis of indeterminate potential, they penetrate tissues 7:49 and we think cause chronic inflammation in the tissues that somehow potentiate 7:53 and cross talks of the tumor to to drive think we hypothesize.
Tumor Crosstalk and Immune Evasion 7:58 And we've got some evidence of this in our clinical studies. 8:00 Poor relapse free survival in early stage lung cancer. 8:03 So we think it makes the metastatic process as well. 8:07 So so it's almost like they then share intelligence. 8:10 Yeah different intelligence agencies and they share intelligence 8:14 to optimize their their goal which is to drive their own survival. 8:19 I think one has to be a little bit careful 8:21 to infer intelligence and an anthropomorphic view of cancer. 8:25 This is simply a result of genetic diversity 8:29 and selection playing out over time. 8:32 There's no intelligence or thought behind this, so we've got to be careful 8:35 not to mislead patients using phrases like cancer's a clever enemy. 8:40 It's not clever. 8:41 It's simply a reflection of just the overwhelming 8:44 genetic diversity that's presence in a, in a, in a solid tumor. 8:48 And so when you say crosstalk, what how does that crosstalk take place? 8:52 And if there's so one obvious example is where tumor cells 8:56 reduce the expression of their or rather, put the brakes on T 9:00 cell immunity through upregulation of checkpoint molecules. 9:04 So they sort of suppress being recognized by the immune cells. 9:09 And they can do this by up regulating receptors like Pd-l1, 9:13 or by losing the flags on the cells 9:16 that allow antigen to be presented, so-called HLA loss. 9:20 So there are multiple ways in which tumor cells adapt over time 9:23 to reduce recognition by the immune system or to dampen down 9:28 immune mediated attack, and that sort of crosstalk 9:30 between a predatory T cell and and its prey, the tumor cell. 9:35 So essentially you're saying it's more of a kind of a natural selection process 9:40 that the epigenetic changes in one sub 9:44 clone is, is kind of what's making it survive. 9:47 And then because it's surviving, then it is then replicating. 9:50 Exactly. Right. Exactly right. Yeah. Okay. 9:54 And so you started you initiated or part of, 9:58 you know, trace or X, you know, that's what you're running right now. 10:01 Are these the kind of questions that are being answered then with that program? 10:06 Yeah, very much so. 10:07 We're studying how tumors are initiated, how they start 10:11 and how they progress over space and time, how they metastasize, 10:15 how they acquire immune evasion, how they acquire resistance to drug therapy, 10:19 ultimately, how they acquire new genome instability mechanisms 10:23 that allow them to become more diverse, genetically diverse over space and time, 10:27 and how all of those biological processes impact clinical outcome. 10:33 And and so 10:34 with that understanding this, you know, 10:37 what are strategies that you feel should be developed in order to be able 10:42 to effectively kind of outsmart these kind of 10:47 genetic selection process that takes place for the cancer's own survival?
TRACE and Cancer Progression Research 10:51 Well, I think the the obvious point is that I made earlier that we need 10:55 to be targeting the trunk, all alterations, 10:57 the founder, mutations, founder events that are present in every tumor cell 11:01 and really finding more and more efficient ways of doing that. 11:04 And we shouldn't take our minds and attention off that challenge. 11:07 We've done. 11:08 Community's done an excellent job so far, but I think we've got further to go. 11:11 I think the second point is the early detection is extremely important. 11:16 So in my disease, in lung cancer, we know that only 11:19 detection of disease improves outcomes. 11:23 And we've got low dose CT screening programs that can detect cancers 11:26 lung cancers before, 11:29 cancers metastasize. 11:30 Once they metastasize, they're largely incurable. 11:33 But in the early stages of disease, 11:34 the majority of patients will be cured by surgery and adjuvant therapy. 11:38 Early detection is crucial. 11:39 So I would say if you're a smoker, have been heavy smoker, engage 11:43 and participate in low dose CT screening programs, that's absolutely crucial. 11:47 And of course prevention and do not, you know, and give up smoking 11:51 if you possibly can. 11:52 And certainly do not start if you haven't smoked. 11:54 And then last but not least, I think well, two points actually. 11:57 Other approaches are sort of early detection of relapse 12:00 after surgical resection. 12:02 In the adjuvant setting. 12:03 We're developing minimal residual disease tools to track tumor evolution 12:07 and escalate therapy in the absence of macroscopic disease 12:11 on a CT scan in patients who have microscopic disease in the blood, 12:15 we want to try to eliminate that while we can maximize the chances of cure. 12:19 And before the disease comes back using tumor informed circulating tumor DNA 12:25 detection approaches, which we've developed through tracer X 12:28 and had had had a lot of success with. 12:31 And last but not least, we're very interested in really going right back 12:34 to the beginning, this big bang of how the tumor starts in the first place. 12:38 And understanding that 12:40 what's becoming increasingly apparent is that it's not all about the mutation.
Targeting Founder Mutations and Early Detection 12:44 You know, 12:45 mutations are important and necessary, but not sufficient to drive cancer. 12:48 What else is required? 12:50 Well, we know increasingly 12:51 that inflammation is required to drive that cancer initiation process, 12:55 and that initiation event is promoted by white blood cells 13:00 like the macrophages that absorb pollutants from our environments, 13:05 either from tobacco exposure or from just air pollution from our urban lives. 13:09 And that chronic inflammation, we think, collaborates with the EGFR 13:13 mutant clones to trigger tumor initiation, and trying to stop that 13:17 with anti-inflammatories or appropriate small molecules or antibody approaches to 13:23 to block key inflammatory processes that collaborate with the EGFR 13:28 activating mutation or the Keras mutation, I think are going to be crucial. 13:32 So the age old adage prevention is better than cure. 13:36 I think it's going to be super important to consider. 13:39 Yeah, I would say the best cancers, the one you never get. 13:42 And obviously early detection and understanding 13:45 the process is going to empower you to be able to be in that position. 13:49 So yeah, I want to get into the circulating tumor DNA a little bit. 13:53 But inflammation. 13:55 So it's centrally if we can control inflammation and also identify 14:01 what is driving the inflammation in individual here. 14:04 Use the example of macrophages absorbing the chemicals from from smoking. 14:10 So is there a way is it essentially then lifestyle 14:15 exposure chemical have metal exposures. 14:18 These type of things that you feel is what initiating that inflammatory process. 14:24 You know 14:24 within the body that can then turn on a lot of these inflammatory drivers. 14:28 Yeah. Yeah I think that's exactly right. 14:30 And I think environmental exposures can do this. 14:33 But also aging the aging process itself can do this. 14:36 So an obvious example is the clonal Mattapoisett example I gave you earlier. 14:40 We know clonal hematopoiesis is associated now with lung cancer risk, 14:45 actually developing lung cancer initiating 14:47 lung cancer and lung cancer progression after surgical resection. 14:51 So and we think the background inflammation 14:53 that chip causes is central to those two processes. 14:57 And we're trying to work out what those are. 14:59 Now we've got some clues from our air pollution work 15:02 that we started about five years ago just before Covid. 15:05 Air pollution has long been known to be a risk factor for lung cancer, 15:08 but people didn't know why. 15:10 We found that air pollutants cause interleukin 15:12 one beta release, and the interleukin one beta collaborates with mutations 15:16 in those epithelial cells to trigger, we think, early tumor initiation. 15:21 Now, there is good evidence for this actually from a trial with an anti one 15:25 beta drug called Cantos, I should say a conflict of interest. 15:28 I've recently been appointed a non-executive director of Novartis. 15:32 The drug is from Novartis, so please bear that in mind. 15:35 Notwithstanding that we did this work before I was appointed 15:38 and what we found is from our in vitro work and our animal work 15:41 that I one beta was important in in tumor radiation, 15:44 and that was very familiar in the context of the Cantos trial that used an anti 15:49 one beta drug in the context of cardiovascular 15:52 risk prevention, which met its primary endpoint. 15:54 But in that trial, they also showed that anti one beta led to a dose 15:59 dependent reduction in new lung cancer primaries during the course 16:03 of the five years of the study, to the extent where 16:05 there was a 67% reduction in new lung cancers at the highest dose. 16:10 I mean, really a phenomenal result,
Inflammation, Aging, and Cancer Initiation 16:12 and one we're very interested in teasing apart and potentially 16:15 trying to mimic in further further studies with potentially new drugs 16:19 to limit inflammation as we age to prevent cardiovascular disease and lung cancer. 16:26 And these are the reasons I 16:28 believe they looked at repurposed drugs like aspirin, Celebrex to help to 16:34 and they've seen impact utilizing those repurposed drugs. 16:38 Yeah, yeah. 16:39 In this case, 16:40 you know, the problem with the term anti-inflammatory is anti-inflammatory. 16:44 And inflammation covers a multitude of biological processes. 16:48 There are a myriad of different inflammatory mechanisms. 16:50 And there's not going to just be one that is that is collaborating 16:54 with those mutated epithelial cells to induce cancer. 16:57 They're going to be several and they're going to be different across tissues. 16:59 I would believe this is one particular target, 17:03 however, that's common to more than one age related pathology. 17:06 I one beta triggers both cardiovascular disease we think and lung cancer. 17:11 And so there's a tantalizing potential that you could reduce 17:15 the risks of two separate age related pathologies by blocking 17:18 one inflammatory pathway, which is tremendously exciting. 17:21 Yeah. 17:22 If you look at cardiovascular and cancer, you get number one. 17:25 And number two in cost of death right there. 17:28 The impact is going to be huge. Exactly. 17:30 And that's what we're going to spend the next ten years working on. 17:34 That's phenomenal. 17:35 And so you're talking about what do you say is 67%. 17:39 Did I hear you right. Yeah. 17:41 67% reduction in the trial. 17:43 And now the bear in mind, this wasn't a pre-specified endpoint. 17:46 It was an analysis that occurred after the study. 17:49 It was mandated by the FDA 17:51 because the FDA were concerned there might be more cancers. 17:53 And in this study, they showed that 67% reduction 17:57 in the number of new lung cancer primaries at the highest dose of anti one beta. 18:00 And it was dose dependent. 18:02 And I would assume that I know you're focusing on on online, 18:06 but I am that this translates over to other types of cancers as well. 18:11 That's a that's a big question. 18:13 Lung cancer is obviously the most one of the most prevalent cancers. 18:16 So they had the greatest power to address that in lung cancer. 18:19 But there were also hints in other cancers too. 18:23 Yeah. 18:23 Okay. 18:23 And you're also talking one of the challenges 18:27 with and monitoring as as the limitations. 18:30 It's only so many times you can do a scan, so much die 18:34 you can put into a body. 18:35 And so there's that limitation then to look and see what what's truly going on. 18:40 And here you brought in 18:42 then being able to monitor it then utilizing then then blood testing. 18:46 You mentioning circulating tumor DNA 18:49 can can you talk a little bit about how we can understand 18:52 utilizing that technology, what's going on with with the cancer. 18:57 So yeah, good question. 18:58 One of the big problems with cycling 19:00 is as you know, it's like looking for a needle in a haystack. 19:03 The amount of time in blood after a surgical procedure is very, 19:07 very low indeed 19:08 and sometimes undetectable in patients who've had successful surgery. 19:11 But we learned from my hematology 19:13 colleagues that minimal residual disease or molecular residuals, residual disease 19:17 is extremely important determinant of outcome. 19:19 And we spent ten years studying this now in lung cancer and tracer X 19:23 through various industry partnerships. 19:25 And we've got very good evidence now that if you have CT DNA 19:29 in your blood, that is DNA derived from the tumor. 19:32 And we know that because we're looking for the same mutations in the 19:36 in the blood that are present in the tumor that's been resected, 19:40 if you have a detectable from the tumor in the blood 19:43 six weeks after surgery, the chance of your tumor 19:47 coming back without any further treatment are very high indeed, well above 90%. 19:52 And that's that looks like it's the same. 19:54 Actually, it's a possibly bit of an exaggeration, but well above 85%. 19:58 It's very high. 19:59 And, that we're learning that's very similar across other tumor types as well.
Circulating Tumor DNA and MRD Monitoring 20:04 And in other words, the positive predictive value for relapse 20:08 in untreated patients in the adjuvant setting, 20:10 if you've gotten DNA in your blood six weeks after surgical resection, is 20:14 is very high indeed. 20:16 So that gives you an opportunity to then offer therapy 20:19 or escalate adjuvant therapies, to try to clear the ctDNA 20:24 and to try to reduce it to undetectable levels. 20:26 And I think it stands to reason from first principles 20:30 that eradication of disease is going to be a lot easier, 20:33 or at least more feasible, I should say, when the burden of disease 20:38 that is the burden of genetic diversity, 20:40 which correlates with the burden of disease, 20:42 is at its lowest point, and that's going to be immediately post-surgery. 20:47 And so there is this tantalizing opportunity 20:49 now where we could start to think about 20:50 bringing late phase trials into the very early phase setting 20:53 and using MRD as a response biomarker, much like we use CT 20:57 imaging in the late phase setting to be able to monitor response 21:02 and benefit from treatment, 21:04 and hopefully find the right drug for the right patient at the right time 21:07 to eradicate their disease, if that makes sense. 21:09 Absolutely. 21:10 And, you know, like you mentioned, I mean, the less diversity. 21:14 So the less tumor burden you have, the more impactful, I would believe, 21:18 you know, something like chemo or whatever therapy 21:21 that is appropriate for that individual would have 21:25 because there is less escape mechanism, sort of say that that's available. 21:30 Yeah. 21:31 Yeah, yeah, I think that's right. 21:33 I'm my assumption and I think this is yet. 21:35 Well actually it is already proven that you can cure patients in the adjuvant 21:39 setting and you can rarely cure patients in the metastatic setting. 21:43 So we know that adjuvant chemotherapy, which rarely ever 21:47 cures patients in the static setting, is associated with somewhere between 21:50 a four and 12% overall survival benefit in the annual setting. 21:55 So that tells you that you can cure relapsing early relapsing 22:00 metastatic disease before it's detectable on a CT scan that you can't do 22:05 once you've got macroscopic evidence of disease on a CT scan. 22:09 And I think that's a crucial and very important observation 22:12 and really has motivated us 22:14 to develop these technologies because of that opportunity. 22:17 Now, in line with that, 22:18 we we found consistent with this in our last paper in this area 22:23 late last year, late 2025, 22:26 in cell, James Black and colleagues, 22:29 we showed that if patients after surgery who get adjuvant chemotherapy 22:34 have a low level of circling tumor DNA below a threshold of 80 parts 22:38 per million, but half of those patients find we can eradicate down 22:44 to undetectable levels CTD and a with adjuvant therapy. 22:48 And those patients, if we eradicate the soap 22:51 carrying human DNA to undetectable levels, those patients have not yet relapsed. 22:56 Now, in contrast, if you have a burden of 22:59 ctDNA above 80 parts per million, we haven't yet 23:03 found an example of a patient whose ctDNA is eradicated by chemotherapy. 23:08 And I think that tells you that potentially the ones we're curing 23:12 are the patients who have very low levels of circulating tumor DNA 23:16 from therapy, and the numbers are small. 23:17 And we've got to we've got a bottom that out in our subsequent tracer studies. 23:21 But that's what it's looking like. 23:24 And so a lot of times 23:26 when a person is dealing with metastatic where you have kind of the initial tumor 23:31 and to now the locations, surgeons are very hesitant. 23:34 And then doing surgery at that time. Yeah. 23:37 So is there with with what you're saying. 23:40 Then if we are able to do surgery 23:43 in some fashion to reduce the tumor burden 23:46 and then bring in the adjuvant type of chemotherapy, obviously 23:50 if the CT DNA is low enough, 23:54 would that be a strategy to be considered? 23:57 It's a it's an excellent question. 23:59 And I think there are a few things I'd like to say about that question.
Metastatic Disease and Aggressive Local Treatment 24:03 Traditionally in my medical oncology training, the the mantra 24:07 is that operating on metastatic disease is relatively futile. 24:11 And where where it's been tested, it hasn't proven of immense value. 24:17 But I think the reality is the answer is much more nuanced 24:20 than that, particularly in the modern era of early detection. 24:24 Only detection of recurrence, lower volume disease, metastatic recurrence, 24:28 newer therapies, newer targeted therapies, but also new radiation approaches 24:32 with stereotactic therapies which have very limited toxicity to normal 24:36 tissue and are very, very accurate in being able to abate 24:39 deep seated metastases. 24:41 And I think those opportunities together 24:44 have changed the landscape of how we manage metastatic disease. 24:47 So that's the clinical perspective. 24:48 The scientific one is as interesting. 24:51 I think we've recently published data from our tracer program 24:54 that was integrated with our autopsy program called piece. 24:58 And in that study, we showed very clearly in lung cancer 25:02 that the majority of metastases seed other metastases. 25:06 In other words the metastases begin to behave like 25:09 new primaries, new primary tumors seeding metastases. 25:13 And so again, it is logical to consider that if a patient has limited number 25:18 of metastatic sites, it would make sense to treat them 25:22 as aggressively as possible to stop them seeding other metastatic size. 25:26 And there there are, you know, increasing number of studies 25:30 that are looking at this, actually with some very tantalizing data 25:33 that suggests that is the case, that operating or ablated 25:37 or treating aggressively metastatic disease improves outcome. 25:42 It's early days, but it's certainly anecdotally something we see quite a lot, 25:46 particularly in, in in oncogene driven 25:49 lung cancers that have been successfully treated with drugs like automotive, 25:53 for example, we see these patients acquire resistant disease. 25:57 Maybe only one site two is after siting treatment. 26:00 And what we often do is oblate that site with 26:04 with stereotactic radiotherapy or surgery and put them back on drug treatment. 26:08 And they're fine for another year or so until 26:11 maybe they develop another metastasis which we ablaze. 26:13 And the cycle continues. 26:14 And we have many patients who've been on treatment 26:16 with surgical procedures or radiation approaches for for, 26:21 which seems to be holding the disease at bay. 26:22 And of course, that's not a randomized study, 26:24 and it's very anecdotal, but my bet is had 26:26 we left those metastases, they would have seeded other metastases. 26:29 And over time we would have lost tumor control that we didn't lose. 26:33 In the context of of this approach of aggressive metastatic management. 26:38 So so centrally, if you can control the the situation because you have 26:43 or we're talking about the the evolution of the cancer in regards to selectivity, 26:49 the their their kind of genetic makeup that makes them resistance to treatment. 26:54 And the further you allow that to take place and more seeding in 26:58 different areas, you're creating more diversity that's harder to treat. 27:02 So if you can kind of hit it harder sooner, 27:06 it is less likely to be like this wildfire that just goes out of control. 27:11 That's right. 27:11 I think that's basically it in a nutshell. 27:13 Yeah. Okay. 27:15 And and you're also so one of the issues is also early detection. 27:20 And you touched on that. 27:22 So with the circulating tumor DNA I mean you need to 27:27 have a biopsy to be able to match that as that's that's correct. 27:31 Right. Yeah. That's correct. Yeah. 27:33 And so how so you can't really use that technology 27:37 in or you can't, you know, that's exactly spot on. 27:40 You can't use a tumor informed approach 27:43 to detect a tumor that you haven't yet detected. 27:46 Because you need to know what the tumor mutations are to create a barcode. 27:50 If you like to detect the tumor in the blood, you need other approaches 27:55 that are tumor agnostic to, to detect cancers in asymptomatic individuals.
Grail Screening and Detecting Aggressive Cancers 28:00 And there are various companies that are developing those tumor agnostic 28:03 approaches, including Grail, that that rely on methylation marks 28:08 from normal tissue and tumor to detect emergent tumors in a patient's body. 28:14 And with Grail, 28:16 the challenges are if it's a tumor that is a slow growing 28:20 kind of one of these little puttering, 28:22 maybe prostate or breast, you know, it is not as easily detectable. 28:26 Yeah. 28:27 But those exactly the tumor types which overdiagnosis is a problem you'll 28:30 recall is the tumor. 28:32 These are the tumors where DCIs and and low grade low 28:35 Gleason score prostate cancers never result in mortality. 28:40 That that that the whole arguments are screening 28:43 is troublesome for because you're over diagnosing tumors 28:46 that will never cause trouble in the patient. 28:49 I think one of the things 28:50 I'm more enthusiastic about the Grail assay is that it detects aggressive tumors 28:54 that really, really need to be managed urgently through surgical resection 28:58 and chemotherapy or adjuvant adjuvant approaches. 29:02 And from your understanding, I mean, because it's always obviously 29:07 Grail then as a, as an expense for the individual, for the patient. 29:11 But it is a phenomenal way of, of screening these aggressive tumors 29:16 that you you really need to kind of step in quickly to, to address. 29:20 So should it be a yearly should it be a biannual? 29:24 I mean, what would be kind of 29:26 an appropriate Tatton for an individual that is concerned? 29:29 So first of all, I probably should declare 29:31 my conflicts of interest here if they're not on the preamble. 29:34 But I sit on the Grail. 29:35 SAB I was chief investigator for the NHS gallery 29:39 randomized 142,000 patients study investigating the grill assay. 29:44 So I've worked on this essay for a time, and I think that's important. 29:48 And we use Grail at our center. 29:50 Yeah. Because I think it's a nominal test. 29:53 So I would have conflict of interest as well. 29:55 So the question is for people that are concerned and and since we're 30:01 dealing with one of the leading causes of death, cancer, and we are screening 30:07 some of the most aggressive type of cancer utilizing technology like Grail. 30:12 What would be an appropriate pattern frequency of testing for an individual? 30:17 Yes. And this is a very good question. 30:20 And I think I talk as a scientist, not as a Grail SAB member here. 30:25 But I think one of the things I've been shocked 30:28 by looking at the data and thinking about the disease 30:31 and thinking about the whole screening paradigm, is that 30:35 the most aggressive cancers have relatively short dwell time. 30:38 So that is, 30:39 they take a relatively short period from inception to metastatic disease. 30:43 And that means that the window of opportunity 30:45 for detection is relatively short, too. 30:48 That is, detection and cure is shorter than I'd imagined. 30:51 And I don't know what the right answer is to your question, 30:55 but I think there is a good case for asking 30:58 would we be better doing the Grail test every six months or every year? 31:02 And I don't know the 31:04 answer to that, but I think it's it's a it's an important question. 31:07 And I think it's important because the time it takes 31:11 for aggressive tumors to migrate from stage 1 to 2 to 3 31:15 to 4 is shorter than I thought it would be 31:18 when we first set this trial up five years ago. 31:22 Yeah, and that's a scary part. 31:24 And it seems to be I had cancer patients. 31:27 They come with a colorectal, and all of a sudden it's in the liver. 31:31 And all of a sudden it's I mean, it just kind of moves quickly or pancreatic 31:35 you can have within three months. 31:37 You know the individual may be, you know, failing treatment. 31:41 So exactly. Yeah it's scary. 31:44 Well, Professor Swanton, this this is phenomenal. 31:47 You're doing incredible work and this is so groundbreaking what you're doing. 31:51 And I really appreciate you taking the time to explain this for our audience. 31:56 So thank you so much. Thank you so much. Love to meet you. 31:59 Thank you I do appreciate it. Pleasure. Thank you. Thank you. Bye
Comments